In This Article:
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), it sends a favourable message to the company's shareholders.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
Check out our latest analysis for BioCryst Pharmaceuticals
The Last 12 Months Of Insider Transactions At BioCryst Pharmaceuticals
The Senior VP Anthony Doyle made the biggest insider purchase in the last 12 months. That single transaction was for US$202k worth of shares at a price of US$5.57 each. Even though the purchase was made at a significantly lower price than the recent price (US$7.87), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months insiders purchased 183.60k shares for US$1.0m. But insiders sold 19.99k shares worth US$123k. Overall, BioCryst Pharmaceuticals insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
BioCryst Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Insider Ownership Of BioCryst Pharmaceuticals
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.0% of BioCryst Pharmaceuticals shares, worth about US$16m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Do The BioCryst Pharmaceuticals Insider Transactions Indicate?
The fact that there have been no BioCryst Pharmaceuticals insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in BioCryst Pharmaceuticals and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of BioCryst Pharmaceuticals.